secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001601830-24-000065
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 4.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting
--------------------------------------------------------------------------------

- Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.
- Board elects Robert Hershberg as new Chair effective at 2024 Annual Meeting; board size reduced from 9 to 8.
- Hershberg, board member since May 2020, is CEO of HilleVax and former Celgene executive with 25+ years experience.
- Auditor changed to PricewaterhouseCoopers for FY 2024 engagement, as previously disclosed on May 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/0001601830-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/rxrx-20240521.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer